Covaxin had much lower adverse effects and overall favourable short-term safety profile in adolescents: Study

Bharat Biotech’s indigenously developed Covid-19 vaccine Covaxin was overall found to have “much lower” AEFI (adverse effects following immunisation) rates in adolescents with a favourable short-term safety profile as compared to those reported with mRNA vaccines but adolescent females and those with a history of allergy were at a 1.6 times and three times increased risk of AEFI after taking Covaxin.
|
||||
|
||||
You Might Like💡 newsR Knowledge: Other News Mentions
|
Shreyas suffered heart attack due to COVID vaccine?Actor Shreyas Talpade shared about his heart attack last year, questioning its possible link to the Covid vaccine. He seeks clarity on whether it's due to Covid...IndiaTimes Also reported by •Mid-Day •Bollywood Life •DNA |
TOI Health News Morning BriefingHere is the TOI health news morning briefing. Legal action against Serum Institute over Covid deaths. AstraZeneca admits side effects. India reports FLiRT COVID...IndiaTimes |
What is Covishield's rare side effect, TTS?Prominent vaccine manufacturer Astra Zeneca acknowledged in a court filing that TTS, a disorder that can result in blood clots and low platelet counts, can be...IndiaTimes Also reported by •DNA |